The Firm represented the underwriters in the global offering and secondary listing of the ordinary shares of Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB) on the Main Board of The Stock Exchange of Hong Kong Limited (the “SEHK”). Zai Lab offered an aggregate of 10,564,050 ordinary shares pursuant to Chapter 19C, a regime introduced by the SEHK to attract listings by high profile issuers that are already listed on the U.S. and London stock exchanges, and Chapter 18A that the SEHK aims to attract listings of new generation of biotech companies. The base offering size was HK$5.94 billion (approximately US$761.1 million) before exercise of the underwriters’ overallotment option. J.P. Morgan, Goldman Sachs and Citigroup acted as the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers for the offering.
Zai Lab is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
The Simpson Thacher team for the transaction included Celia Lam, Yi Gao, Carol Chan, Chenjing Shen, Cherrie Zhang, Yi-Ping Chang and Christy Li (Capital Markets – Hong Kong); Art Robinson, Jean Park and John O’Connell (Capital Markets – New York); Marcy Geller, Tyler Robbins and Jasmine Hay (Tax); and Jennie Getsin (FINRA).